Category Medicine and Healthcare
![Nerve Freedom Reviews [Investigated Complaints] Best Neuropathy Supplement for Nerve Pain Relief Naturally](https://cdn.nwe.io/files/x/db/c2/7594195487c7d963773c03dd7543.jpg)
Press Release
Nerve Freedom Reviews [Investigated Complaints] Best Neuropathy Supplement for Nerve Pain Relief Naturally
Discover the truth behind Nerve Freedom's neuropathy relief claims as we investigate real user complaints, review clinical ingredients like Alpha Lipoic Acid and Turmeric, and compare long-term results, pricing, and expert recommendations for the best natural nerve pain support in 2025. Read More
Press Release
Best Testosterone Supplement for Men Over 40 and 50: Testosil for Muscle Gain & Erectile Dysfunction 2025
Testosil by Leading Edge Health is a clinically-backed natural testosterone booster formulated for men over 40 and 50, designed to support muscle growth, energy, mood, and intimate health by boosting testosterone up to 434% - without synthetic hormones or stimulants. Read More
Press Release
Industry Experts Review the Best NMN Supplement Brands in 2025
Leading Health Edge's GenuinePurity™ Liposomal NMN Emerges as the 2025 Industry Benchmark for Anti-Aging Supplements With 96%+ Purity, Superior Bioavailability, and Third-Party Verified Pharmaceutical-Grade Quality Read More
Press Release
Alleviating the Pain of CRPS Gave Heather Her Life Back: The Spero Clinic's Role in the Recovery
Is it possible that a simple sound can hurt you? That the sound of a bird singing in the yard can make you scream out in pain? That's the reality of having CRPS. Here's how the Spero Clinic helped Heather get her life back. Read More
Press Release
Notable Systems Strengthens Leadership Team
Notable Systems continues to expand its executive team with two key appointments: Brian Nannie, former Chief Data Officer at Lincare, joins as Senior Vice President of Client Strategy & Innovation, and Gaurav Nukala, former Head of Product Operations at Innovaccer, assumes the role of Senior Vice President of Product. These strategic hires strengthen Notable's leadership team with deep expertise in DME, HME, and healthcare revenue cycle management. Read More
Press Release
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogs Jaguar in discussions with potential partners to license and fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs Read More
Press Release
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model
Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival. Building on previous data in Werner syndrome, showing Telomir-1 reset the epigenetic clock, extended telomere length, restored gene expression, reversed muscle loss, and rescued survival-alongside data in Age Related Macular Degeneration (AMD) demonstrating retinal regeneration and restored vision-the drug continues to show broad regenerative potential across rare genetic degenerative diseases Read More
Press Release
Interactive Strength Inc. (Nasdaq:TRNR) Enters into $500 Million Facility to Acquire AI-focused $FET Tokens and Launch Crypto Treasury Asset Strategy
ATW Partners and DWF Labs invested $55 million in initial closing TRNR is expected to have the largest US publicly listed crypto treasury focused on an AI-token TRNR enters into technology collaboration with Fetch.ai to power its fitness training with AI technology Read More
Press Release
CBD Life Sciences Inc. (CBDL) Reports 1,502.30% Revenue Increase from January to May 2025
Achieving a five-month revenue growth equivalent to an annualized rate exceeding 4,000%, as the booming CBD and mushroom supplement markets-projected to reach $30 billion and $15 billion respectively by 2028-fuel strong consumer demand and industry expansion. Read More
Press Release
Black Book Research Demonstrates Two-Decade Commitment to Excellence in Managed Care Industry Insights
In-Depth, Transparent Industry Studies Highlight Leading IT Solutions, Managed Services, Outsourcing, and Advisory Firms Serving Health Plans Since 2004; AHIP Conference to Showcase Top Vendor Recognitions Read More
Press Release
ZetrOZ Systems Supports the Next Generation of Physician-Scientists with Sponsorship of the Orthopaedic Foundation's Medical Immersion Program
The inventor of sustained acoustic medicine and the sam® wearable ultrasound technologies support students at an internationally known summer program and funds student and professional research through its STEM Scholarship Program. Read More
Press Release
Black Book Research Highlights 15 Top-Rated Healthcare IT Vendors Exhibiting at HIMSS 25 Europe in Paris
HIMSS25 Europe takes place June 10-12, 2025 at the Palais des Congrès in Paris, showcasing the latest digital health innovations and driving collaboration across the European healthcare IT ecosystem. Read More
Press Release
Dr. Meegan Gruber Shares Insight on Plastic Surgery Transparency: How Younger Generations Are Shaping a New Era of Body Authenticity
A culture change is affecting how people talk about cosmetic surgery, from popular TikToks to BBL reversals. Dr. Meegan Gruber shows why choices made with knowledge and power are becoming more critical. Read More
Press Release
Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
Michael Howe - who currently serves as an Independent Board Member - to assume CEO role on June 10, 2025 Michael's career spans nationally recognized brands such as MinuteClinic, Procter & Gamble, PepsiCo, CEO of Arby's, and as an early-stage investor/board member in healthcare and software businesses Read More
Press Release
DEA DIVERSION Scandal Exposed - Marijuana Drug Development Obstruction
DEA Back to Training School, DEA Bureaucrat Blocks Science While Ignoring their Own TRAINING Manual. DEA Assistant Administrators and attorney needs a summer assignment, and MMJ BioPharma Cultivation has a suggestion: go back and read your own policy statement and training manual. Read More
Press Release
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan
Gross proceeds from offering total $16.6 million. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders. Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD. EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo. EXXUA is expected to serve as a major growth catalyst as Aytu continues to build value for shareholders; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts. Conference call to discuss the EXXUA opportunity and commercialization plan scheduled for Wednesday, June 11, 2025, at 4:30 p.m. Eastern time. Read More
Press Release
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Click here to register Discussion will focus on company's May 2025 meeting with the FDA to review the statistically significant responder analysis results for the subgroup of breast cancer patients in company's recently conducted Phase 3 OnTarget trial The currently estimated US metastatic breast cancer population potentially qualifies as an orphan population, in alignment with company's core focus on orphan diseases Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer Read More
Press Release
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies The currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with company's core focus on orphan diseases Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer Read More
Press Release
Dedalus Named Europe's Top-Rated EHR for Workflow Alignment in Black Book Report Ahead of HIMSS25 Paris
Independent Global Study Evaluates EHR Satisfaction Across 110 Countries; 93% of European Users Say Dedalus Clinical Documentation Tools Better Align with Local Workflows than U.S. Vendors Read More
Press Release
DEA's Marijuana Defiance Deepens: Rogue Bureaucrats Undermine DOJ, Supreme Court, and Rule of Law
Terrance Cole's First Test: Will He Restore DEA Diversion To Legitimacy As the DEA Diversion spirals into constitutional crisis, all eyes now turn to incoming Administrator Terrance Cole. With the Supreme Court, DOJ, and Congress aligned on the illegality of the agency's ALJ system, Cole faces a clear mandate: dismantle the DEA's kangaroo court framework, remove corrupt leadership like Thomas Prevoznik, Matthew Strait and attorney Aarathi Haig, restore sound marijuana policy and return the agency to the rule of law. His next moves will determine whether the DEA Diversion can be salvaged-or whether it must be restructured from the ground up. Read More
Press Release
Greece’s Digital Health Reset: Opportunities Emerge for Local EHR and Interoperability Vendors Amid Lagging IT Infrastructure, Black Book Research
Independent Survey Reveals Gaps in Greek Healthcare IT, Underscoring Urgent Need for Homegrown Digital Solutions and Modernization Partnerships Read More
Press Release
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD. EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo. EXXUA is expected to serve as a major growth catalyst as Aytu continues to build value for shareholders; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts. EXXUA transaction financed by long-term, healthcare-focused institutional investors, including Aytu's largest shareholder Nantahala Capital Management, Stonepine Capital Management, Aytu management, and new institutional shareholders. Read More
Press Release
MMJ BioPharma Clarifies Remarks Regarding Curaleaf and International Cannabis Distribution
Terrance Cole, the nominee for Administrator of the U.S. Drug Enforcement Administration (DEA), stands at a pivotal juncture with the opportunity to address longstanding issues related to the agency's handling of cannabis policy. Read More
Press Release
Au Pair USA Highlights New Report Showing Strong Positive Impact of Au Pair Programs in the U.S.
The 2025 report, commissioned by the Alliance for International Exchange, provides further evidence of the key cultural and financial benefits of au pair programs for American families Read More
Press Release
